|
1
|
Aydin MM and Akcali KC: Liver fibrosis.
Turk J Gastroenterol. 29:14–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hernandez-Gea V and Friedman SL:
Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parola M and Pinzani M: Liver fibrosis:
Pathophysiology, pathogenetic targets and clinical issues. Mol
Aspects Med. 65:37–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun M and Kisseleva T: Reversibility of
liver fibrosis. Clin Res Hepatol Gastroenterol. 39 (Suppl
1):S60–S63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jarroux J, Morillon A and Pinskaya M:
History, discovery, and classification of lncRNAs. Adv Exp Med
Biol. 1008:1–46. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robinson EK, Covarrubias S and Carpenter
S: The how and why of lncRNA function: An innate immune
perspective. Biochim Biophys Acta Gene Regul Mech. 1863:1944192020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jathar S, Kumar V, Srivastava J and
Tripathi V: Technological developments in lncRNA biology. Adv Exp
Med Biol. 1008:283–323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu J, Fu H, Wu Y and Zheng X: Function of
lncRNAs and approaches to lncRNA-protein interactions. Sci China
Life Sci. 56:876–885. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murillo-Maldonado JM and Riesgo-Escovar
JR: The various and shared roles of lncRNAs during development. Dev
Dyn. 248:1059–1069. 2019. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bian EB, Xiong ZG and Li J: New advances
of lncRNAs in liver fibrosis, with specific focus on lncRNA-miRNA
interactions. J Cell Physiol. 234:2194–2203. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He Z, Yang D, Fan X, Zhang M, Li Y, Gu X
and Yang M: The roles and mechanisms of lncRNAs in liver fibrosis.
Int J Mol Sci. 21:14822020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanson A, Wilhelmsen D and DiStefano JK:
The role of long non-coding RNAs (lncRNAs) in the development and
progression of fibrosis associated with nonalcoholic fatty liver
disease (NAFLD). Noncoding RNA. 4:182018.PubMed/NCBI
|
|
14
|
Zhang K, Han X, Zhang Z, Zheng L, Hu Z,
Yao Q, Cui H, Shu G, Si M, Li C, et al: The liver-enriched
lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch
pathways. Nat Commun. 8:1442017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang K, Han Y, Hu Z, Zhang Z, Shao S, Yao
Q, Zheng L, Wang J, Han X, Zhang Y, et al: SCARNA10, a
nuclear-retained long non-coding RNA, promotes liver fibrosis and
serves as a potential biomarker. Theranostics. 9:3622–3638. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Z, Lin CY and Cheng K: siRNA- and
miRNA-based therapeutics for liver fibrosis. Transl Res. 214:17–29.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lan T, Li C, Yang G, Sun Y, Zhuang L, Ou
Y, Li H, Wang G, Kisseleva T, Brenner D and Guo J: Sphingosine
kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated
inhibition of CCR2. Hepatology. 68:1070–1086. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qu Y, Zhang Q, Cai X, Li F, Ma Z, Xu M and
Lu L: Exosomes derived from miR-181-5p-modified adipose-derived
mesenchymal stem cells prevent liver fibrosis via autophagy
activation. J Cell Mol Med. 21:2491–2502. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feili X, Wu S, Ye W, Tu J and Lou L:
MicroRNA-34a-5p inhibits liver fibrosis by regulating TGF-β1/Smad3
pathway in hepatic stellate cells. Cell Biol Int. 42:1370–1376.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Petersen BW, Harms TJ, Reynolds MG and
Harrison LH: Use of vaccinia virus smallpox vaccine in laboratory
and health care personnel at risk for occupational exposure to
orthopoxviruses-recommendations of the advisory committee on
immunization practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep.
65:257–262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khatun M, Sur S, Steele R, Ray R and Ray
RB: Inhibition of long noncoding RNA linc-pint by hepatitis C virus
in infected hepatocytes enhances lipogenesis. Hepatology. 74:41–54.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Campana L and Iredale JP: Regression of
liver fibrosis. Semin Liver Dis. 37:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang CY, Yuan WG, He P, Lei JH and Wang
CX: Liver fibrosis and hepatic stellate cells: Etiology,
pathological hallmarks and therapeutic targets. World J
Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao Y, Liu R, Li X, Gurley EC, Hylemon
PB, Lu Y, Zhou H and Cai W: Long noncoding RNA H19 contributes to
cholangiocyte proliferation and cholestatic liver fibrosis in
biliary atresia. Hepatology. 70:1658–1673. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peng H, Wan LY, Liang JJ, Zhang YQ, Ai WB
and Wu JF: The roles of lncRNA in hepatic fibrosis. Cell Biosci.
8:632018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen MJ, Wang XG, Sun ZX and Liu XC:
Diagnostic value of LncRNA-MEG3 as a serum biomarker in patients
with hepatitis B complicated with liver fibrosis. Eur Rev Med
Pharmacol Sci. 23:4360–4367. 2019.PubMed/NCBI
|
|
28
|
Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang
X, Gurley EC, Liang G, Chen W, Lai G, et al: Cholangiocyte-derived
exosomal long noncoding RNA H19 promotes hepatic stellate cell
activation and cholestatic liver fibrosis. Hepatology.
70:1317–1335. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen X, Guo H, Xu J and Wang J: Inhibition
of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis
by inhibiting the MAPK signaling pathway in rats with nonalcoholic
fatty liver disease. J Cell Physiol. 234:18169–18179. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng J, Wang C, Liu T, Li J, Wu L, Yu Q,
Li S, Zhou Y, Zhang J, Chen J, et al: Procyanidin B2 inhibits the
activation of hepatic stellate cells and angiogenesis via the
Hedgehog pathway during liver fibrosis. J Cell Mol Med.
23:6479–6493. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang Y: The novel regulatory role of
lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med.
22:5768–5775. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen L, Zhou Y and Li H: LncRNA, miRNA and
lncRNA-miRNA interaction in viral infection. Virus Res. 257:25–32.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsay HC, Yuan Q, Balakrishnan A, Kaiser M,
Mobus S, Kozdrowska E, Farid M, Tegtmeyer PK, Borst K, Vondran FWR,
et al: Hepatocyte-specific suppression of microRNA-221-3p mitigates
liver fibrosis. J Hepatol. 70:722–734. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caviglia JM, Yan J, Jang MK, Gwak GY, Affo
S, Yu L, Olinga P, Friedman RA, Chen X and Schwabe RF: MicroRNA-21
and Dicer are dispensable for hepatic stellate cell activation and
the development of liver fibrosis. Hepatology. 67:2414–2429. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Calvente CJ, Tameda M, Johnson CD, Del
Pilar H, Lin YC, Adronikou N, De Mollerat Du Jeu X, Llorente C,
Boyer J and Feldstein AE: Neutrophils contribute to spontaneous
resolution of liver inflammation and fibrosis via microRNA-223. J
Clin Invest. 129:4091–4109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zeng C, Wang YL, Xie C, Sang Y, Li TJ,
Zhang M, Wang R, Zhang Q, Zheng L and Zhuang SM: Identification of
a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling
cascade and its implication in hepatic fibrogenesis. Oncotarget.
6:12224–12233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jia C, Tang D, Sun C, Yao L, Li F, Hu Y,
Zhang X and Wu D: MicroRNA466 inhibits the aggressive behaviors of
hepatocellular carcinoma by directly targeting metadherin. Oncol
Rep. 40:3890–3898. 2018.PubMed/NCBI
|
|
38
|
Abdel-Al A, El-Ahwany E, Zoheiry M, Hassan
M, Ouf A, Abu-Taleb H, Abdel Rahim A, El-Talkawy MD and Zada S:
miRNA-221 and miRNA-222 are promising biomarkers for progression of
liver fibrosis in HCV Egyptian patients. Virus Res. 253:135–139.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McCarthy AJ and Chetty R: Smad4/DPC4. J
Clin Pathol. 71:661–664. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao M, Mishra L and Deng CX: The role of
TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 14:111–123. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu XB, He ZP, Leng XS, Liang ZQ, Peng JR,
Zhang HY, Zhang HY, Xiao M, Zhang H, Liu CL and Zhang XD: Effects
of Smad4 on liver fibrosis and hepatocarcinogenesis in mice treated
with CCl4/ethanol. Zhonghua Gan Zang Bing Za Zhi. 18:119–123.
2010.(In Chinese). PubMed/NCBI
|
